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study was to evaluate structured chiropodist care (CC) with
regard to healing rates and costs provided by intensively
instructed professionals. METHODS: One year follow-up-data
of a randomized and controlled trial (RCT) performed in the
province of Styria, Austria showed signiﬁcantly reduced reulcer-
ation rates under chiropodist care. Patients in the intervention
group received chiropodist care in average 11 times per year and
were reimbursed for the costs (€29 per visit). Based on a pub-
lished paper Austrian speciﬁc cost data of 2001 were used to
build a Markov Model to evaluate 10 years outcome. A Monte-
Carlo-Simulation (n = 10.000) was performed for patients with
chiropodist care (intervention) and no chiropodist care (control).
RESULTS: Mean follow-up-duration for 91 patients of the RCT
was 386 days with a reulceration rate of 36% in the interven-
tion group (n = 47) and 55% in the control group (p = 0.05).
The model calculation over 10 years showed treatment costs per
patient of €12,094 (SD 13,379) in the intervention and €18,538
(SD 16,120) in the control group. Costs for the general treat-
ment of diabetes were not taken into account. The amputation
rate under intervention declined to 40% versus 67% in the
control group. Taking the mean life expectancy into account (6.1
vs. 5.1ys.) average costs per patient-year were 1.985 € in the
intervention group versus €3.654 in the control group. CON-
CLUSION: The model based analysis demonstrated the beneﬁt
of CC over a 10 year period in terms of reduced amputation rates
and lower costs per patient and year.
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OBJECTIVES: Hyperglycemia in the critically ill, non-diabetic
patient has been shown to negatively affect clinical outcomes.
Administration of continuous insulin infusion (CII) to maintain
blood glucose (BG) between 80–110mg/dL has thus become
standard of care. The objective of this study was to compare the
costs and BG levels associated with glucose control among
patients pre- and post-CII protocol implementation in an inten-
sive care unit (ICU). METHODS: Combination of time-in-
motion (TIM) observations and retrospective random chart
review to compare glucose control and costs in 2001 and 2004,
prior to and after CII implementation respectively. TIM data
determined time spent on activities related to glucose manage-
ment and chart data determined frequency of respective activi-
ties per year. Study population included ICU patients >16 years
old, mechanically ventilated for >12 hours, with no diagnosis of
diabetes. Costs were determined for glucose monitoring with no
insulin orders (2001), glucose management with sliding scale
subcutaneous insulin (2001), and management with CII proto-
col (2004) using 2005 US$ from the hospital perspective.
RESULTS: From a total 460 charts in 2001, 49 (11%) were
reviewed. From a total 540 charts in 2004, 83 (15%) were
reviewed. No differences in age, gender, marital status, or race
by year were noted (p > 0.05). Costs (mean +/-SD) associated
with monitoring and no insulin were $0.16 +/-0.56 (median =
$0.00) per patient day, with subcutaneous insulin $10.08 
+/-4.96 (median = $8.42), and with CII protocol $21.87 +/-3.90
(median = $22.49). Mean +/-SD daily blood glucose values 
were 138mg/dL +/-24, 157mg/dL +/-32, and 108mg/dL +/-10,
respectively. Regression analysis demonstrated statistical differ-
ences in BG (p < 0.01) by method. CONCLUSION: Costs asso-
ciated with CII protocol are more than twice the costs of sliding
scale subcutaneous orders per patient day, but result in recom-
mended BG values below 110mg/dL. Impact of costs on hospi-
tal policy will be discussed.
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OBJECTIVES To evaluate the long-term clinical and economic
outcomes of adding Niaspan® to statin treatment in Type-2 dia-
betes patients with persistently low HDL-c. METHODS Two
models were developed to project long-term clinical and eco-
nomic beneﬁts. The ﬁrst simulated the evolution of lipid levels
with treatment utilising second order Monte Carlo methodology,
and the second was designed to calculate the risk of coronary
heart disease (CHD) events each subsequent year using standard
Markov modeling techniques. Transition probabilities for CHD
events were derived from the Framingham risk formulae. Base-
line cohort characteristics and simvastatin treatment effects were
taken from the 4S clinical trial (diabetes sub-group). Patients
with persistently low HDL-c (<1mmol/L) on statin treatment
received either add-on Niaspan® or continued statin monother-
apy. Treatment effects of Niaspan® were taken from several clin-
ical studies summarized in the European SPC. Direct costs (2004
Euros) were accounted from a third party payer perspective.
Annual discount rates of 5% (Germany) and 3% (Sweden) were
applied to clinical outcomes and costs. RESULTS A total of
23.42% of patients were projected to have persistently low
HDL-c levels after statin treatment. In these patients mean undis-
counted life expectancies of 19.72 years and 19.13 years were
projected for the Niaspan® and statin monotherapy arms respec-
tively (undiscounted difference 0.59 years). Improvements in 
discounted life expectancy were 0.26 and 0.35 years respec-
tively for Germany and Sweden. Lifetime direct medical costs
were higher by €6,038 in Germany and €6,170 (SEK 56,308) 
in Sweden with addition of Niaspan®. Incremental cost-
effectiveness ratios based on discounted life expectancies were
€23,404 in Germany and €17,538 (SEK 160,099) per life year
gained in Sweden for statin plus Niaspan® versus statin
monotherapy. CONCLUSIONS In Germany and Sweden, addi-
tion of Niaspan® to statin treatment was highly cost-effective in
Type-2 diabetes patients with persistently low HDL-c compared
to statin monotherapy.
PDB18
COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE
NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS
NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA: A UK
PERSPECTIVE
Paschen B1, Roze S2, Palmer AJ2,Valentine WJ2, Liens D3,
Renaudin C3
1Merck KGaA, Darmstadt, Germany; 2CORE—Center for Outcomes
Research, Binningen, Basel, Switzerland; 3Merck Santé, Lyon, France
OBJECTIVES: To compare the long-term cost-effectiveness of
adding Niaspan® to statin treatment in diabetic and non-diabetic
patients with persistently low HDL c. METHODS: Two models
were developed to project long-term clinical and economic out-
comes. The ﬁrst model (Monte Carlo simulation) was used to
evaluate the impact of simvastatin treatment on lipid levels and
identify patients with low HDL-c. Baseline cohort characteristics
were taken from the diabetic sub-population of the 4S study. In
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patients with HDL-c <1mmol/L, treatment with statin plus add-
on Niaspan® was compared to statin monotherapy. Niaspan®
treatment effects were taken from several clinical trials as sum-
marized in the European SPC. The second model (Markov) sim-
ulated the development of coronary heart disease events based
on the Framingham risk formulae. Direct medical costs were
accounted from a third-party payer perspective in the UK and
expressed in pounds sterling (£). Annual discount rates of 3.5%
were applied to clinical and cost outcomes. RESULTS: Niaspan®
was associated with improvements in mean discounted life
expectancy in diabetic (0.32 years) and non-diabetic cohorts
(0.29 years) compared to statin monotherapy. Similarly,
improvements in quality-adjusted life expectancy of (diabetic)
0.26 and (non-diabetic) 0.23 quality-adjusted life years (QALYs)
were projected. Niaspan® was associated with increases in mean
lifetime costs of £4492 (diabetic) and £4891 (non-diabetic)
versus statin alone. This led to incremental cost-effectiveness
ratios of £17,296 per QALY gained in the diabetic cohort and
£21,150 in the non-diabetic cohort. CONCLUSIONS: Addition
of Niaspan® to statin treatment was cost-effective by generally
accepted standards compared to statin monotherapy in patients
with persistently low HDL-c in the UK. In patients with Type-2
diabetes and an associated high risk of CHD events, add-on
therapy with Niaspan® represented better value for money than
in non-diabetic patients.
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OBJECTIVES: To project the long-term clinical and cost out-
comes associated with long-acting insulin analog treatment in
patients with type-1 diabetes in an Austrian setting. METHODS:
We used a published, validated and peer-reviewed computer sim-
ulation model of diabetes to project short-term clinical ﬁndings
to evaluate long-term outcomes including quality-adjusted life
expectancy, complication rates and direct medical costs. Clinical
data have been derived from the PREDICTIVE study, an ongoing
global post-marketing safety study, for a sub-group of patients
with type-1 diabetes receiving long-acting insulin glargine (IGlar)
in a basal/bolus treatment regimen at baseline and switched to
long-acting insulin detemir (IDet). After 12 weeks of follow up,
IDet-based basal/bolus treatment was associated with improve-
ments in HbA1c (0.25%-points lower), reduced risk of hypo-
glycemic events (by 55%), and decreased body weight (0.27kg)
compared to IGlar-based treatment. Probabilities of complica-
tions and HbA1c-dependent adjustments were derived from the
DCCT, Framingham, and WESDR studies (amongst others).
Costs of treating complications were retrieved from published
sources. Total direct costs (complications + treatment costs) were
projected over patient lifetimes. Costs and outcomes were dis-
counted at 3.5% per annum. RESULTS: Improved glycemic
control, decreased hypoglycemic events and BMI with IDet-
based basal/bolus therapy led to fewer diabetes-related compli-
cations and an increase in quality-adjusted life expectancy of
0.13 quality-adjusted life years (QALYs). IDet-based therapy was
associated with slightly higher lifetime direct costs (€394 per
patient) which led to an incremental cost-effectiveness ratio
(ICER) of €3031 per QALY gained. CONCLUSIONS: Short-
term clinical beneﬁts associated with IDet-based basal/bolus
therapy were projected to lead to improvements in quality-
adjusted life expectancy and fewer diabetes related complications
than IGlar-based regimens. Incremental cost-effectiveness analy-
sis indicated that, over patient lifetimes, IDet-based combina-
tions would represent good value for money versus IGlar-based
therapy in the Austrian setting.
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OBJECTIVES: To project long-term clinical and cost outcomes
associated with biphasic insulin aspart 30 (BIAsp 30) and oral
hypoglycemic agents (OHAs) in a Swedish setting based on the
ﬁndings of a randomized clinical trial. METHODS: A published,
validated and peer-reviewed model of diabetes was used to sim-
ulate the progression of diabetes-related complications based on
clinical trial data which showed that switching to BIAsp 30 sig-
niﬁcantly reduced HbA1c compared to continuation of OHAs in
insulin-naïve patients with Type-2 diabetes over 16 weeks (dif-
ference in HbA1c reduction 0.648%; p < 0.001). Direct medical
costs were accounted from a third party payer perspective in
Sweden and expressed in 2004 Swedish Kroner (SEK). Costs and
clinical beneﬁts were discounted at 3% annually and sensitivity
analyses were performed on treatment effect, time horizon and
discount rates. RESULTS: BIAsp 30 was projected to extend 
life expectancy (mean [standard deviation]) by 0.47 [0.22] com-
pared to OHAs (11.38 vs. 10.90 years). Quality-adjusted life
expectancy was improved with BIAsp 30 by 0.42 [0.15] quality-
adjusted life years (QALYs) versus OHAs (7.94 vs. 7.52 QALYs).
BIAsp 30 was associated with a lower cumulative incidence of
diabetes-related complications, particularly retinopathy and
nephropathy. Mean direct lifetime costs were higher in the BIAsp
30 group (SEK 286,467 [11,745]) than in patients receiving
OHAs (SEK 272,752 [12,885]), a difference of SEK 13,716
[17,030], leading to an incremental cost-effectiveness ratio of
SEK 32,736 per QALY gained. Sensitivity analysis showed that
these ﬁndings were robust under variation in a range of assump-
tions. CONCLUSIONS: Switching to BIAsp 30 was projected to
reduce the incidence of diabetes-related complications, and
improve life expectancy and quality-adjusted life expectancy,
compared to continuation of OHAs in Type-2 diabetes patients.
Switching to BIAsp 30 was projected to represent good value for
money by internationally accepted standards in the Swedish
setting.
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OBJECTIVES: In patients with type-1 diabetes, poor glycemic
control is associated with an increased risk of complications. A
recent clinical study provided evidence that basal/bolus treat-
ment with insulin detemir + insulin aspart (IDet/IAsp) improved
HbA1c (0.22%-points lower after 18 weeks), reduced the risk of
hypoglycemic events (by 21%), and decreased body mass index
